Akebia Therapeutics Inc
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialy… Read more
Akebia Therapeutics Inc (AX9) - Total Liabilities
Latest total liabilities as of September 2025: €322.56 Million EUR
Based on the latest financial reports, Akebia Therapeutics Inc (AX9) has total liabilities worth €322.56 Million EUR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Akebia Therapeutics Inc - Total Liabilities Trend (2015–2024)
This chart illustrates how Akebia Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Akebia Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Akebia Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Boston Omaha Corp
NYSE:BOC
|
USA | $173.43 Million |
|
Medigen Vaccine Biologics
TWO:6547
|
Taiwan | NT$461.06 Million |
|
Jiangsu Fasten Co Ltd
SHE:000890
|
China | CN¥937.05 Million |
|
Jiangsu Flag Chemical Industry Co Ltd
SHE:300575
|
China | CN¥2.65 Billion |
|
Atlanticus Holdings Corporation
NASDAQ:ATLC
|
USA | $6.45 Billion |
|
Great Taipei Gas Corp
TW:9908
|
Taiwan | NT$5.64 Billion |
|
Nova Minerals Limited
NASDAQ:NVA
|
USA | $2.69 Million |
Liability Composition Analysis (2015–2024)
This chart breaks down Akebia Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.94 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 7.76 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.89 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Akebia Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Akebia Therapeutics Inc (2015–2024)
The table below shows the annual total liabilities of Akebia Therapeutics Inc from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €269.86 Million | -0.89% |
| 2023-12-31 | €272.29 Million | -20.50% |
| 2022-12-31 | €342.49 Million | -23.74% |
| 2021-12-31 | €449.09 Million | +13.26% |
| 2020-12-31 | €396.52 Million | +5.33% |
| 2019-12-31 | €376.44 Million | +4.39% |
| 2018-12-31 | €360.61 Million | +47.24% |
| 2017-12-31 | €244.92 Million | +5.52% |
| 2016-12-31 | €232.10 Million | +1843.53% |
| 2015-12-31 | €11.94 Million | -- |